nektar therapeutics (NKTR:NASDAQ GS)
Earnings & Estimates Summary - NEKTAR THERAPEUTICS (NKTR)
2013 revenues at Nektar Therapeutics totaled $148.9M USD, while annual losses equaled $1.40 per share.
Quarterly Earnings & Estimates - NEKTAR THERAPEUTICS (NKTR)
Nektar Therapeutics's Quarterly Earnings
Nektar Therapeutics reported 1st quarter 2014 losses of $0.37 per share on 05/9/2014.
Annual Earnings & Estimates - NEKTAR THERAPEUTICS (NKTR)
Nektar Therapeutics's Annual Earnings
Nektar Therapeutics reported annual 2013 losses of $1.40 per share on 02/28/2014.
Quarterly Revenues - NEKTAR THERAPEUTICS (NKTR)
Nektar Therapeutics's Quarterly Revenues
Nektar Therapeutics had 1st quarter 2014 revenues of $19.8M USD. This missed the $38.7M USD consensus estimate of the 8 analysts following the company. This was -14.1% below the prior year's 1st quarter results.
Annual Revenues - NEKTAR THERAPEUTICS (NKTR)
Nektar Therapeutics's Annual Revenues
Nektar Therapeutics had revenues for the full year 2013 of $148.9M USD. This was 83.4% above the prior year's results.
|Depomed Inc||$10.69 USD||-0.35|
|Emergent Biosolutions Inc||$22.45 USD||+0.18|
|Ironwood Pharmaceuticals Inc||$15.18 USD||+0.08|
|Skyepharma PLC||246.00 GBp||+0.75|
|Veloxis Pharmaceuticals A/S||kr1.99 DKK||-0.01|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|